aTYR PHARMA INC (ATYR) Earnings
aTYR PHARMA INC's most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Nov 5, 2026
From the latest earnings 8-K
Revenue • FY2025
$190K
▼ 19.1%YoY
Diluted EPS • FY2025
-$0.80
▲ 7.0%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from ATYR's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $190K | -$74.12M | — | -$0.80 | -$62.06M | -40856.3% | -19.1% |
| FY2024 | $235K | -$64.02M | — | -$0.86 | -$69.18M | -28899.6% | -33.4% |
| FY2023 | $353K | -$50.39M | — | -$0.94 | -$37.44M | -15557.8% | -96.6% |
| FY2022 | $10.39M | -$45.34M | — | -$1.60 | -$43.53M | -446.8% | — |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Nov 5, 2026 | 8-K (2.02) | 0001339970-26-000076EDGAR |
| Aug 7, 2026 | 8-K (2.02) | 0001339970-26-000051EDGAR |
| May 15, 2026 | 8-K (2.02) | 0001339970-26-000030EDGAR |
| May 11, 2026 | 8-K (2.02) | 0001339970-26-000027EDGAR |
| Mar 5, 2026 | 8-K (2.02) | 0001339970-26-000006EDGAR |
| Nov 6, 2025 | 8-K (2.02) | 0001193125-25-269486EDGAR |
| May 7, 2025 | 8-K (2.02) | 0000950170-25-065611EDGAR |
| Mar 13, 2025 | 8-K (2.02) | 0000950170-25-038703EDGAR |
Never miss a ATYR filing.
Get an email when ATYR files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 8, 2026Source: SEC EDGAR.